Literature DB >> 33800219

Circulating Renalase as Predictor of Renal and Cardiovascular Outcomes in Pre-Dialysis CKD Patients: A 5-Year Prospective Cohort Study.

Ana Cerqueira1,2,3, Janete Quelhas-Santos2,3, Inês Ferreira1,2,3, Susana Sampaio1,2,3, Miguel Relvas1, Nídia Marques1, Cláudia Camila Dias4,5, Manuel Pestana1,2,3.   

Abstract

Chronic kidney disease (CKD) is an independent risk factor for adverse cardiovascular and cerebrovascular events (MACCEs), and mortality since the earlier stages. Therefore, it is critical to identify the link between CKD and cardiovascular risk (CVR) through early and reliable biomarkers. Acknowledging that CKD and CKD progression are associated with increased sympathetic tone, which is implicated in CVR, and that renalase metabolizes catecholamines, we aimed to evaluate the relationship between renalase serum levels (RNLS) and cardiovascular and renal outcomes. The study included 40 pre-dialysis CKD patients (19F:21M) with median age of 61 (IQ 45-66) years. At baseline, we measured RNLS as well as routine biomarkers of renal and cardiovascular risk. A prospective analysis was performed to determine whether RNLS are associated with CKD progression, MACCEs, hospitalizations and all-cause mortality. At baseline, the median level of RNLS and median estimated glomerular filtration rate (eGFR) were 63.5 (IQ 48.4-82.7) µg/mL and 47 (IQ 13-119) mL/min/1.73 m2, respectively. In univariate analysis, RNLS were strongly associated with eGFR, age and Charlson Index. Over the course of a mean follow-up of 65 (47 to 70) months, 3 (7.5%) deaths, 2 (5%) fatal MACCEs, 17 (42.5%) hospital admissions occurred, and 16 (40%) patients experienced CKD progression. In univariate analysis, RNLS were associated with CKD progression (p = 0.001), hospitalizations (p = 0.001) and all-cause mortality (p = 0.022) but not with MACCEs (p = 0.094). In adjusted analysis, RNLS predicted CKD progression and hospitalizations regardless of age, Charlson comorbidity index, cardiovascular disease, hypertension, diabetes and dyslipidemia. Our results suggest that RNLS, closely related with renal function, might have a potential role as predictor of renal outcomes, hospitalizations, and mortality in pre-dialysis CKD patients.

Entities:  

Keywords:  CKD progression; MACCEs; cardiovascular risk; chronic kidney disease; renalase

Year:  2021        PMID: 33800219      PMCID: PMC7999882          DOI: 10.3390/life11030210

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  36 in total

1.  The assessment of renalase: searching for the best predictor of early renal dysfunction by multivariate modeling in stable renal transplant recipients.

Authors:  Dijana Stojanovic; Tatjana Cvetkovic; Miodrag Stojanovic; Vladmila Bojanic; Nikola Stefanovic; Ivana Stojanovic
Journal:  Ann Transplant       Date:  2015-04-02       Impact factor: 1.530

Review 2.  Cardiovascular risk in chronic kidney disease.

Authors:  Nagesh S Anavekar; Marc A Pfeffer
Journal:  Kidney Int Suppl       Date:  2004-11       Impact factor: 10.545

3.  Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.

Authors:  Giovanni Tripepi; Francesco Mattace Raso; Eric Sijbrands; Mohamed Sidy Seck; Renke Maas; Rainer Boger; Jacqueline Witteman; Francesco Rapisarda; Lorenzo Malatino; Francesca Mallamaci; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-03       Impact factor: 8.237

4.  The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.

Authors:  F Irie; H Iso; T Sairenchi; N Fukasawa; K Yamagishi; S Ikehara; M Kanashiki; Y Saito; H Ota; T Nose
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

5.  Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients.

Authors:  Edyta Zbroch; Jolanta Małyszko; Jacek Małyszko; Ewa Koc-Żórawska; Michał Myśliwiec
Journal:  Pol Arch Med Wewn       Date:  2012-01-11

6.  Increased serum renalase in peritoneal dialysis patients: Is it related to cardiovascular disease risk?

Authors:  Ebru Gok Oguz; Hadim Akoglu; Gulay Ulusal Okyay; Guner Karaveli Gursoy; Tolga Yildirim; Ozgur Merhametsiz; Tolga Cimen; Basol Canbakan; Ekrem Yeter; M Deniz Ayli
Journal:  Nefrologia       Date:  2017-02-01       Impact factor: 2.033

Review 7.  The burden of chronic kidney disease on developing nations: a 21st century challenge in global health.

Authors:  Rachel A Nugent; Sana F Fathima; Andrea B Feigl; Dorothy Chyung
Journal:  Nephron Clin Pract       Date:  2011-01-07

8.  Renalase, stroke, and hypertension in hemodialyzed patients.

Authors:  Jolanta Malyszko; Ewa Koc-Zorawska; Jacek S Malyszko; Piotr Kozminski; Edyta Zbroch; Michal Mysliwiec
Journal:  Ren Fail       Date:  2012-05-14       Impact factor: 2.606

9.  Serum Renalase Levels Are Predicted by Brain-Derived Neurotrophic Factor and Associated with Cardiovascular Events and Mortality after Percutaneous Coronary Intervention.

Authors:  I-Te Lee; Wayne Huey-Herng Sheu
Journal:  J Clin Med       Date:  2018-11-12       Impact factor: 4.241

10.  Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients.

Authors:  Natalia M Serwin; Magda Wiśniewska; Elżbieta Cecerska-Heryć; Krzysztof Safranow; Edyta Skwirczyńska; Barbara Dołęgowska
Journal:  BMC Nephrol       Date:  2020-03-04       Impact factor: 2.388

View more
  2 in total

1.  Elevated Levels of Renalase, the β-NAD(P)H Isomerase, Can Be Used as Risk Factors of Major Adverse Cardiovascular Events and All-Cause Death in Patients with Chronic Kidney Disease.

Authors:  Wojciech Knop; Natalia Maria Serwin; Elżbieta Cecerska-Heryć; Bartłomiej Grygorcewicz; Barbara Dołęgowska; Aleksandra Gomółka; Magda Wiśniewska; Kazimierz Ciechanowski
Journal:  Biomolecules       Date:  2021-10-14

Review 2.  Renalase: a novel regulator of cardiometabolic and renal diseases.

Authors:  Anupama Vijayakumar; Nitish R Mahapatra
Journal:  Hypertens Res       Date:  2022-08-08       Impact factor: 5.528

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.